How to buy DiaMedica Therapeutics stock

DiaMedica Therapeutics Inc is a biotechnology business based in the US. DiaMedica Therapeutics shares (DMAC) are listed on the NASDAQ and all prices are listed in US Dollars. DiaMedica Therapeutics employs 8 staff and has a market cap (total outstanding shares value) of USD$172.4 million.

How to buy shares in DiaMedica Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for DiaMedica Therapeutics. Find the stock by name or ticker symbol: DMAC. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until DiaMedica Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of DiaMedica Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of DiaMedica Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced investors

Webull

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.

What's in this guide?

1. DMAC shares summary
2. Compare share dealing platforms
3. Is DMAC stock a buy or sell?
4. Stock performance over time
5. Can I short DMAC shares?
6. DiaMedica Therapeutics's financials
7. How volatile are DMAC shares?
8. Does DiaMedica Therapeutics pay a dividend?
9. Have DMAC shares ever split?
10. Other common questions

DiaMedica Therapeutics share price

Use our graph to track the performance of DMAC stocks over time.

DiaMedica Therapeutics shares at a glance

• Key figures

Information last updated 2021-03-03.

52-week range	USD$1.87 - USD$10.88
50-day moving average	USD$9.2659
200-day moving average	USD$6.361
Wall St. target price	USD$19.83
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.895

Buy DiaMedica Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Webull		$0	Stocks, Options, ETFs	$0	0%	Get two free stock valued between $2.50 and $250 Open an account	Margin financing rates start at 3.99%. No monthly subscription fees for margin.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy DiaMedica Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of DiaMedica Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting DiaMedica Therapeutics shares

There are currently 82,969 DiaMedica Therapeutics shares held short by investors – that's known as DiaMedica Therapeutics's "short interest". This figure is 10.9% down from 93,069 last month.

There are a few different ways that this level of interest in shorting DiaMedica Therapeutics shares can be evaluated.

DiaMedica Therapeutics's "short interest ratio" (SIR)

DiaMedica Therapeutics's "short interest ratio" (SIR) is the quantity of DiaMedica Therapeutics shares currently shorted divided by the average quantity of DiaMedica Therapeutics shares traded daily (recently around 169324.48979592). DiaMedica Therapeutics's SIR currently stands at 0.49. In other words for every 100,000 DiaMedica Therapeutics shares traded daily on the market, roughly 490 shares are currently held short.

However DiaMedica Therapeutics's short interest can also be evaluated against the total number of DiaMedica Therapeutics shares, or, against the total number of tradable DiaMedica Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DiaMedica Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 DiaMedica Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0047% of the tradable shares (for every 100,000 tradable DiaMedica Therapeutics shares, roughly 5 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DiaMedica Therapeutics.

Find out more about how you can short DiaMedica Therapeutics stock.

Have DiaMedica Therapeutics's shares ever split?

DiaMedica Therapeutics's shares were split on a 1:20 basis on 15 November 2018. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your DiaMedica Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for DiaMedica Therapeutics shares which in turn could have impacted DiaMedica Therapeutics's share price.

DiaMedica Therapeutics share price volatility

Over the last 12 months, DiaMedica Therapeutics's shares have ranged in value from as little as $1.87 up to $10.88. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DiaMedica Therapeutics's is 2.4258. This would suggest that DiaMedica Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

DiaMedica Therapeutics overview

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.

Frequently asked questions

• What percentage of DiaMedica Therapeutics is owned by insiders or institutions?

  Currently 6.715% of DiaMedica Therapeutics shares are held by insiders and 39.313% by institutions.

• How many people work for DiaMedica Therapeutics?

  Latest data suggests 8 work at DiaMedica Therapeutics.

• When does the fiscal year end for DiaMedica Therapeutics?

  DiaMedica Therapeutics's fiscal year ends in December.

• Where is DiaMedica Therapeutics based?

  DiaMedica Therapeutics's address is: 2 Carlson Parkway, Minneapolis, MN, United States, 55447

• What is DiaMedica Therapeutics's ISIN number?

  DiaMedica Therapeutics's international securities identification number is: CA25253X2077

• What is DiaMedica Therapeutics's CUSIP number?

  DiaMedica Therapeutics's Committee on Uniform Securities Identification Procedures number is: 25253X207